SCHEMBL2840258

SCHEMBL2840258

CC(C)(C)OC(=O)N1C[C@](O)(CO)C[C@H]1COc1c(F)ccc2c(=O)c(C(=O)OCc3ccccc3)cn(C3CC3)c12

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.37
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
STAT3 P40763 1/20 0.34
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
ABCB1 P08183 1/20 0.32
HPGD P15428 1/20 0.32
ADRB2 P07550 1/20 0.31
KCNH2 Q12809 2/20 0.31
KLK7 P49862 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
AGTR2 P50052 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2840255 1.00 GSK3B (0.37) GSK3BKDM4EALDH1A1LMNAPOLB
SCHEMBL2840344 0.85 GSK3B (0.38) GSK3BKDM4EALDH1A1LMNAPOLB
SCHEMBL2840345 0.85 GSK3B (0.38) GSK3BKDM4EALDH1A1LMNAPOLB
SCHEMBL585457 0.82 STAT3 (0.41) KDM4EALDH1A1TDP1STAT3TSHR
SCHEMBL2845823 0.81 GSK3B (0.39) GSK3BKDM4EALDH1A1LMNAPOLB
Hydrochloric Acid SCHEMBL2843272 0.81 GSK3B (0.39) GSK3BKDM4EALDH1A1LMNAPOLB
SCHEMBL2840260 0.78 GSK3B (0.36) GSK3BKDM4EALDH1A1LMNAPOLB
SCHEMBL2841900 0.78 STAT3 (0.42) GSK3BKDM4EALDH1A1LMNAPOLB
SCHEMBL2847619 0.78 STAT3 (0.42) GSK3BKDM4EALDH1A1LMNAPOLB
SCHEMBL2845727 0.78 STAT3 (0.42) GSK3BKDM4EALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222302-A1 Novel Antibacterial Compounds ACTELION PHARMACEUTICALS LTD (CH) 2010-09-02 US claimed
EP-2256120-A1 Oxazolidinone-quinolone hybrids as antibacterial compounds Actelion Pharmaceuticals Ltd. (CH) 2010-12-01 EP disclosed
US-20100222302-A1 Novel Antibacterial Compounds ACTELION PHARMACEUTICALS LTD (CH) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222302-A1 Novel Antibacterial Compounds ODC1, AOC1, OGFOD1 GSK3B 4330/4885KDM4E 2548/4885ALDH1A1 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.